Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial  by Anagnostou, Katherine et al.
Articles
www.thelancet.com   Vol 383   April 12, 2014 1297
Assessing the eﬃ  cacy of oral immunotherapy for the 
desensitisation of peanut allergy in children (STOP II): 
a phase 2 randomised controlled trial
Katherine Anagnostou, Sabita Islam, Yvonne King, Loraine Foley, Laura Pasea, Simon Bond, Chris Palmer, John Deighton, Pamela Ewan, Andrew Clark
Summary
Background Small studies suggest peanut oral immunotherapy (OIT) might be eﬀ ective in the treatment of peanut 
allergy. We aimed to establish the eﬃ  cacy of OIT for the desensitisation of children with allergy to peanuts.
Methods We did a randomised controlled crossover trial to compare the eﬃ  cacy of active OIT (using characterised 
peanut ﬂ our; protein doses of 2–800 mg/day) with control (peanut avoidance, the present standard of care) at the 
NIHR/Wellcome Trust Cambridge Clinical Research Facility (Cambridge, UK). Randomisation (1:1) was by use of an 
audited online system; group allocation was not masked. Eligible participants were aged 7–16 years with an immediate 
hypersensitivity reaction after peanut ingestion, positive skin prick test to peanuts, and positive by double-blind 
placebo-controlled food challenge (DBPCFC). We excluded participants if they had a major chronic illness, if the care 
provider or a present household member had suspected or diagnosed allergy to peanuts, or if there was an 
unwillingness or inability to comply with study procedures. Our primary outcome was desensitisation, deﬁ ned as 
negative peanut challenge (1400 mg protein in DBPCFC) at 6 months (ﬁ rst phase). Control participants underwent 
OIT during the second phase, with subsequent DBPCFC. Immunological parameters and disease-speciﬁ c quality-of-
life scores were measured. Analysis was by intention to treat. Fisher’s exact test was used to compare the proportion 
of those with desensitisation to peanut after 6 months between the active and control group at the end of the ﬁ rst 
phase. This trial is registered with Current Controlled Trials, number ISRCTN62416244.
Findings The primary outcome, desensitisation, was recorded for 62% (24 of 39 participants; 95% CI 45–78) in the active 
group and none of the control group after the ﬁ rst phase (0 of 46; 95% CI 0–9; p<0·001). 84% (95% CI 70–93) of the 
active group tolerated daily ingestion of 800 mg protein (equivalent to roughly ﬁ ve peanuts). Median increase in peanut 
threshold after OIT was 1345 mg (range 45–1400; p<0·001) or 25·5 times (range 1·82–280; p<0·001). After the second 
phase, 54% (95% CI 35–72) tolerated 1400 mg challenge (equivalent to roughly ten peanuts) and 91% (79–98) tolerated 
daily ingestion of 800 mg protein. Quality-of-life scores improved (decreased) after OIT (median change –1·61; p<0·001). 
Side-eﬀ ects were mild in most participants. Gastrointestinal symptoms were, collectively, most common (31 participants 
with nausea, 31 with vomiting, and one with diarrhoea), then oral pruritus after 6·3% of doses (76 participants) and 
wheeze after 0·41% of doses (21 participants). Intramuscular adrenaline was used after 0·01% of doses (one participant).
Interpretation OIT successfully induced desensitisation in most children within the study population with peanut 
allergy of any severity, with a clinically meaningful increase in peanut threshold. Quality of life improved after 
intervention and there was a good safety proﬁ le. Immunological changes corresponded with clinical desensitisation. 
Further studies in wider populations are recommended; peanut OIT should not be done in non-specialist settings, 
but it is eﬀ ective and well tolerated in the studied age group.
Funding MRC-NIHR partnership.
Introduction
Allergy to peanuts is an increasingly common and 
important medical disorder, aﬀ ecting 0·5–1·4% of 
children in high-income countries.1,2 Peanut allergy is 
the most common cause of severe and fatal allergic 
reactions related to food, it is diﬃ  cult to identify people 
at highest risk,3 and resolution is uncommon.4 Quality of 
life is reduced because of the likelihood of anaphylaxis, 
causing constant fear over food choices.5,6 Despite 
present management, families have poor knowledge of 
how to avoid and treat food allergy emergencies.7 
Accidental reactions are common, with annual 
incidences of 14–55%.8–10
Therefore, there is a need for a disease-modifying 
therapy. Immunotherapy is an established treatment for 
inhalant allergies11,12 and insect-venom anaphylaxis.13 
Early studies of subcutaneous immunotherapy for 
peanut allergy were associated with severe adverse 
reactions, possibly due to the route of administration.14 
The oral route might be associated with greater safety, 
and has been studied in egg and milk allergy.15,16
There is a need for systematic study of oral immuno-
therapy (OIT) for the treatment peanut allergy. Therefore, 
after a phase 1 study that showed good tolerability,17,18 our 
aim was to establish the eﬃ  cacy of OIT for the 
desensitisation of children with allergy to peanuts. 
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Method
Participants
Between January, 2010, and March, 2013, we did a single-
centre phase 2 randomised controlled two-phase trial at 
the NIHR/Wellcome Trust Cambridge Clinical Research 
Facility (Cambridge, UK). During the ﬁ rst phase the 
active group underwent 26 weeks of peanut OIT, and the 
control group underwent 26 weeks of standard care 
(peanut avoidance). At the end of the ﬁ rst phase 
(26 weeks) all participants were assessed for peanut 
allergy by double-blind placebo-controlled food challenge 
(DBPCFC). During the second phase, participants in the 
control group still allergic to peanuts were oﬀ ered peanut 
OIT, with a subsequent further DBPCFC.
Participants were recruited both locally (allergy clinic) 
and nationally (through national patient support group 
Anaphylaxis Campaign). Eligible participants were aged 
7–16 years with an immediate hypersensitivity reaction 
after peanut ingestion, positive skin prick test to peanut 
(extract ALK-Abello, Hørsholm, Denmark) deﬁ ned by 
weal of 3 mm or larger in the presence of a negative 
saline and positive histamine control, and positive 
DBPCFC.19 We excluded participants if they had a major 
chronic illness (except for eczema, rhinitis, or asthma) 
since this was an immunomodulatory therapy, if the 
care provider or present household member had 
suspected or diagnosed allergy to peanuts, or if there 
was an unwillingness or inability to comply with study 
procedures. We did not exclude participants who had a 
previous life-threatening reaction, tree-nut allergy, or a 
history of severe asthma.
The Cambridge Central Ethics Committee approved 
the study (09/H0308/154) and the guardian of each 
participant gave written informed consent. Children of 
an appropriate age were encouraged to provide their 
own assent. The University of Cambridge and 
Cambridge University Hospitals NHS Trust (RD 
authorisation A091686) jointly sponsored the study.
104 participants assessed for eligibility
99 entered randomisation
5 excluded (did not meet inclusion criteria)
49 allocated to receive active intervention
 49 received intervention
 0 did not receive intervention
0 lost to follow-up
1 discontinued (not possible to increase dose)
5 withdrew
 1 disliked taste
 2 had frequent reactions
 1 had persistent symptoms
 1 had no reason
0 lost to follow-up
1 discontinued (developed Crohn’s disease)
50 allocated to receive control intervention
 47 received intervention
 3 did not receive intervention (did not want 
  control intervention)
0 lost to follow-up
0 discontinued
2 withdrew (had frequent reactions)
46 allocated to receive active intervention
 45 received intervention
 1 did not receive intervention
 1 allergy was too mild for OIT (parents’ opinion)
49 analysed
10 excluded from primary analysis (did not have 
  post-OIT DBPCFC)
46 analysed
 0 tolerant to peanut exposure
 46 allergic to peanuts
45 analysed
 0 excluded from analysis
Figure 1: Trial proﬁ le
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Randomisation and masking
Participants were randomly assigned (1:1) via an audited 
online system (Randomizer, Medical University of Graz, 
Austria) to receive either the active therapy or the control 
intervention. Minimisation was used to reduce imbalance 
of baseline covariates, with a random element using a 
weighting probability of 0·8. Factors were sex, age, 
challenge threshold, peanut speciﬁ c serum IgE, severity 
from history, and presence of asthma or other food 
allergy. Group allocation was not masked.
Procedures
The active intervention (OIT) was given in daily doses of 
characterised peanut ﬂ our (light roast ﬂ our; Golden Peanut 
Company, Alphretta, GA, USA). First, there was a gradual 
updosing phase with 2 week increments to protein doses 
of 800 mg/day, and subsequently a maintenance period 
where the highest tolerated dose (with a target of 800 mg/
day) was taken daily to complete a total of 26 weeks OIT. 
We devised a novel updosing regime, diﬀ erent from other 
published protocols (patent pending): doses were 2 mg, 
5 mg, 12·5 mg, 25 mg, 50 mg, 100 mg, 200 mg, 400 mg, 
and 800 mg of peanut protein.18 The rationale for choosing 
a daily maintenance dose of 800 mg was on the basis of the 
highest amount of peanut protein used in the pilot study 
that participants were able to ingest on an ongoing daily 
basis, which was also associated with a suggestion of 
eﬃ  cacy. Peanut protein was presented as a ﬁ nely ground 
defatted powder that was mixed into food before ingestion. 
Dose increments took place in the NIHR/Wellcome Trust 
Clinical Research Facility and participants were observed 
for 2 h. The same dose was then given at home daily for 
2–3 weeks. Participants were asked to take their dose with 
food and instructed not to exercise for 2 h after taking a 
dose. Participants were asked to complete symptom diaries 
and were provided with adrenaline autoinjectors. At the 
end of the study participants were encouraged to continue 
daily consumption of 800 mg peanut protein.
Outcomes
The primary outcome was the proportion of desensitised 
participants in each group at the end of the ﬁ rst phase. 
Desensitisation was deﬁ ned as no reaction during peanut 
DBPCFC with a cumulative dose of 1400 mg peanut 
protein. The primary outcome was assessed for all 
participants together and also by recruitment group 
(local or national).
Secondary outcomes were the proportion of participants 
who tolerated daily ingestion of 800 mg protein (equivalent 
to ﬁ ve peanuts) up to 26 weeks; the proportion of the 
control group who were desensitised or tolerated daily 
ingestion of 800 mg protein during the second phase; the 
fold and absolute increase in threshold (maximum 
tolerated peanut protein in mg) after OIT—deﬁ ned as no 
observed adverse eﬀ ect level (NOAEL; highest dose of 
peanut protein tolerated in mg protein during challenge 
or immunotherapy); the change in quality-of-life score; 
the number and type of adverse events; the change in 
immunological outcomes (basophil area under curve of 
CD63% and mean ﬂ uorescent intensity [MFI], peanut 
speciﬁ c IgE, total IgE, and skin prick test weal diameter).
All peanut challenges were done as DBPCFCs in 
accordance with best practice,19 using separate active and 
placebo phases and masked with the validated EuroPrevall 
dessert food carrier recipe (range of doses from 5, 50, 100, 
300, and 1000 mg peanut protein).20 We chose a cumulative 
challenge dose equivalent to roughly ten peanuts to show 
desensitisation to an amount of peanut that we judged 
unlikely to be encountered accidentally after OIT. Random 
number lists established the order of DBPCFC placebo 
and active arms. All study personnel were masked to the 
challenge assignment except the scientist who prepared 
the challenge material; they had no interaction with the 
participant or study team. 
Quality of life was measured by a disease-speciﬁ c 
questionnaire, the Food Allergy Quality of Life—Parent 
Form (FAQLQ-PF), available for 0–12 years.21 Hence this 
questionnaire was only oﬀ ered to families with a child 
aged 7–12 years. The questionnaire was scored on a six-
point scale, averaged over three areas with equal 
weighting: emotional impact, food anxiety, and social 
and dietary limitation. Scores were obtained from 
baseline and the end of each phase. 
Flow cytometric analysis (ﬂ uorescence-activated cell 
sorting) of patient samples was done on whole-blood 
specimens to quantify the proportion and MFI of CD63 
basophils. Skin prick tests were done with standardised 
peanut extract from ALK-Abello, (Hørsholm, Denmark) 
and a single point lancet. Peanut speciﬁ c IgE was 
measured with the ImmunoCap system (Thermo 
Scientiﬁ c, Waltham, MA, USA). Measurements were 
made at baseline and after each phase.
Control (n=46) Active (n=39) p value
First phase
Number desensitised 0 24 <0·001*
Number not desensitised 46 15
Proportion desensitised 0 (0 to 0·091) 0·62 (0·45 to 0·78) ··
Proportion able to tolerate daily ingestion 0 0·84 (0·70 to 0·93) ··
Median absolute change in NOAEL, mg 0 (–95 to 45) 1345 (45 to 1400) 0·002, <0·001†
Median fold change in NOAEL, mg 0·81 (0·05 to 1·82) 25·5 (1·82 to 280) 0·003, <0·001†
Median NOAEL after ﬁ rst phase, mg‡ 5 (5 to 400) 1400 (100 to 1400) <0·001§
Second phase
Proportion desensitised 0·54 (0·35 to 0·72) ·· ··
Proportion able to tolerate daily ingestion 0·91 (0·79 to 0·98) ·· ··
Median change in FAQLQ-PF score from 
baseline to post-treatment
–1·41 
(–4·83 to 1·38)¶
–1·61 
(–4·87 to 0·24)||
<0·001, 
<0·001**
Data are proportion (95% CI) or median (range). NOAEL=no observed adverse eﬀ ect level. FAQLQ-PF=Food Allergy 
Quality of Life Questionnaire—Parent Form for 5–12 years. *From Fisher’s exact test. †From Wilcoxon signed rank tests. 
‡Median diﬀ erence in NOAEL between groups was 1395 mg (95% CI 395 to 1395); p<0·001 (from Mann Whitney 
U test). §From Mann Whitney U test. ¶n=20. ||n=19. **From Wilcoxon signed rank tests.
Table 1: Clinical endpoints for ﬁ rst and second phases
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Statistical analyses
All analyses were planned prospectively and detailed in a 
statistical analysis plan. Fisher’s exact test was used 
to compare the proportion of participants with 
desensitisation to peanut after 6 months between the 
active and control group at the end of the ﬁ rst phase. 
Exact unconditional conﬁ dence limits for the absolute 
risk diﬀ erence were calculated. Secondary analyses tested 
for treatment diﬀ erences with Fisher’s exact test 
(proportion response to treatment in active group and 
control group at end of the second phase), Wilcoxon 
signed rank tests (absolute and fold change in threshold), 
and Mann-Whitney U test (diﬀ erence between groups in 
quality-of-life scores, basophil area under curve of 
CD63% and MFI, peanut-speciﬁ c IgE, and skin prick test 
weal diameter). 
Tobit regression22 was used in preference to linear 
regression, because it is better suited to analysis of 
censored dependent variables. We expected a large 
number of NOAEL values to be right censored at 1400 mg, 
as successfully desensitised participants would not react 
to this top dose during challenge. Estimates were provided 
for treatment on 6 month NOAEL adjusted for baseline 
covariates. All statistical tests described use a two-sided 
5% signiﬁ cance level. Intention-to-treat analysis was done 
on the full analysis population that included all 
participants who were randomised and participated in at 
least one post-baseline assessment (DBPCFC). 
Sample size was based on Fisher’s exact test with 90% 
power and 5% signiﬁ cance (two-sided). A sample size of 
49 in each group is suﬃ  cient to detect proportions of 
participants with desensitisation to peanut of 0·64 and 
0·30 in the active and control groups respectively at the 
end of the ﬁ rst phase. Allowing for 5% dropout increased 
the sample size to 52 participants in each group and 
104 overall. Based on the above we would expect 
35 waiting list group participants to proceed to the active 
intervention in the second phase. 
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Figure 1 shows the trial proﬁ le. We enrolled 104 children, 
aged 7–16 years (median 12·4 years). The baseline 
characteristics of the participants are listed in the 
appendix. Five children did not react during their 
baseline peanut challenge. Therefore 99 children were 
randomly assigned to the study groups: 49 active and 
50 control (ﬁ gure 1). One child discontinued and ﬁ ve 
withdrew from the active group during the ﬁ rst phase. 
Four further participants were excluded from the primary 
analysis because they had not reached the target 
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Figure 3: In-vitro basophil activation by peanut before and after desensitisation
Heparinised whole blood was stimulated with a range of peanut protein concentrations (0·001–100 μg/mL) and 
ﬂ ow cytometry was used to assess expression as a proportion of CD63 positive cells (A) or by MFI (B) within the 
basophil population. Diﬀ erences in areas under the curve were not signiﬁ cant. MFI=mean ﬂ uorescent intensity. 
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Figure 2: Peanut protein NOAEL by treatment group
Points show the mean and whiskers the 95% CIs. Diﬀ erence at 6 months 
p<0·001 (from Mann Whitney U test). NOAEL=no observed adverse eﬀ ect level.See Online for appendix
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maintenance OIT dose at 6 months. In the control group, 
four children withdrew and one discontinued during the 
ﬁ rst phase.
There was a signiﬁ cant diﬀ erence between the 
proportions of participants who had no reaction to 
1400 mg peanut protein during DBPCFC at the end of 
the ﬁ rst phase in the active (24 of 39 participants; 62%, 
95% CI 45–78%) compared with the control group 
(0 of 46; 0%, 95% CI 0–9·1; p<0·001; table 1). The 
absolute risk diﬀ erence was estimated as 62% with a 
conservative 95% CI of 43–77. There was no signiﬁ cant 
diﬀ erence in primary outcome between locally and 
nationally recruited participants (data not shown).
84% (95% CI 70–93) of the active group at the end of 
the ﬁ rst phase, and 91% (79–98) of the control group at 
the end of the second phase (after OIT) were able to 
tolerate daily ingestion of 800 mg protein for 26 weeks. 
There was a signiﬁ cant increase in peanut NOAEL in the 
active group after the ﬁ rst phase, with a median change 
in threshold of 25·5 times (p<0·001; table 1) compared 
with a small negative change in peanut threshold 
(NOAEL) in the control group during the ﬁ rst phase 
(0·81, range 0·05–1·82; ﬁ gure 2). 
Quality-of-life scores assessed by the FAQLQ-PF 
instrument21 were similar in active and control groups at 
baseline. Both groups showed a similar and clinically 
meaningful improvement (decrease) in quality of life 
scores after treatment (table 1).
Immunological assessments showed a signiﬁ cant 
small reduction in median skin prick test weal diameter 
and increase in peanut-speciﬁ c IgE after 24 weeks OIT in 
the active group (appendix). Basophil stimulation test 
data were expressed as the area under the curve (AUC) of 
plots of MFI and proportion of CD63-positive cells 
against concentration of peanut protein. No signiﬁ cant 
within-patient diﬀ erences were identiﬁ ed after treatment 
for AUC of MFI or proportion of CD63, although there 
was a reduction in MFI and proportion of CD63 at lower 
peanut concentrations after OIT (ﬁ gure 3).
Tobit regression suggested several baseline covariates 
could aﬀ ect the ﬁ nal NOAEL (table 2). Baseline NOAEL, 
World Allergy Organization grade 2 reaction, and total 
IgE were also associated with higher post-OIT NOAEL. 
Age, family history, weight, and peanut-speciﬁ c IgE were 
associated with lower ﬁ nal NOAEL.
The number and nature of adverse events was similar 
in both groups after treatment. Most events were mild 
with oral itching being the most common (occurring 
after 6·3% of all doses; table 3). Cutaneous events were 
uncommon, present after only 0·16% of doses. Wheezing 
occurred after 0·41% of doses in 22% of participants and 
was treated with inhaled β2 agonists and oral 
antihistamines alone in all cases except for one parti-
cipant who, additionally, self-administered intra muscular 
adrenaline on two occasions, with rapid resolution of his 
symptoms. There were no serious adverse reactions and 
no cardiovascular events.
Estimate (95% CI) p value
Oral immunotherapy 105·5 (67·73–164·40) <0·001
Log (baseline NOAEL + 1) 1·40 (1·15–1·69) <0·001
Age 0·76 (0·65–0·89) <0·001
Female 1·42 (0·87–2·31) 0·16
Weight 1·04 (1·01–1·06) 0·004
Quality of life 1·12 (0·89–1·42) 0·32
Asthma 1·09 (0·65–1·74) 0·79
Eczema 0·82 (0·53–1·26) 0·36
Rhinitis 0·69 (0·46–1·05) 0·09
Other food allergy 0·84 (0·52–1·36) 0·48
Family history of peanut allergy 0·41 (0·24–0·71) 0·001
WAO grade 2 2·88 (1·65–5·01) <0·001
WAO grade 3 0·86 (0·44–1·68) 0·66
WAO grade 4 0·62 (0·21–1·82) 0·40
Peanut SPT wheal diameter 1·02 (0·94–1·11) 0·60
Other nut SPT wheal diameter >3 mm 1·37 (0·81–2·31) 0·23
Tryptase 1·06 (0·95–1·19) 0·32
Log (peanut speciﬁ c IgE + 1) 0·60 (0·51–0·71) <0·001
Log (total IgE + 1) 1·74 (1·35–2·23) <0·001
Log (basophil activation CD63 MFI AUC) 0·98 (0·73–1·32) 0·91
NOAEL is the highest amount of peanut protein (mg) tolerated after OIT. The continuous variables can be interpreted 
as the percentage change in NOAEL expected from a unit increase of that variable when all other covariates are ﬁ xed. 
The categorical variable estimates can be interpreted as the percentage change compared with the reference group 
when all other covariates are ﬁ xed. For logged covariates the expected percentage change in 6 month NOAEL with a 
10% increase in the logged covariate can be calculated as 1·10^log (exponentiated estimate). For example, for a 10% 
increase in baseline NOAEL (mg) we would expect a [1·1^log(1·40)=1·032] 3·2% increase in 6 month NOAEL (mg). 
Similarly, for a 10% increase in baseline peanut speciﬁ c IgE (kU/L) we would expect a 4·8% decrease in 6 month NOAEL 
(mg). NOAEL=no observed adverse eﬀ ect level. OIT=oral immunotherapy. WAO=World Allergy Organization. SPT=skin 
prick test. MFI=mean ﬂ uorescent intensity. AUC=area under the curve. 
Table 2: Tobit regression model exponentiated estimates—dependent variable natural log 6-month NOAEL
Participants who 
experience an 
adverse event
Adverse events per 
dose of OIT
Symptoms
Mouth itch 76 (81%) 1121 (6·30%)
Abdominal pain 54 (57%) 460 (2·59%)
Nausea 31 (33%) 393 (2·21%)
Vomiting 31 (33%) 134 (0·75%)
Diarrhoea 1 (1%) 5 (0·03%)
Urticaria 12 (13%) 29 (0·16%)
Angio-oedema 18 (19%) 71 (0·40%)
Erythema 20 (21%) 41 (0·23%)
Rhinitis 23 (24%) 65 (0·37%)
Wheezing 21 (22%) 73 (0·41%)
Laryngeal oedema 1 (1%) 1 (0·01%)
Cardiovascular collapse or fainting 0 0
Outcome
Admission to intensive-care unit, serious adverse reaction, or 
serious unexpected suspected adverse reaction
0 0
Use of inhaled β2 agonist 18 (19%) 63 (0·35%)
Use of intramuscular adrenaline 1 (1%) 2 (0·01%)
Data are n (%). Total doses were 17 793. OIT=oral immunotherapy.
Table 3: Adverse events during treatment presented
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Discussion
Daily doses of peanut OIT of up to 800 mg protein had 
a clinically meaningful eﬀ ect, shown by a high 
incidence of desensitisation, large absolute and fold 
increases in threshold (NOAEL), and a signiﬁ cant 
improvement in quality-of-life score; 84% of participants 
in ﬁ rst phase and 91% in the second phase could 
tolerate daily ingestion roughly equivalent to ﬁ ve 
peanuts per day. To our knowledge, our ﬁ ndings 
provide the ﬁ rst well controlled and accurate estimate 
of the eﬀ ect size, beneﬁ ts, and risks of desensitisation 
with peanut OIT (panel). 
Raising the reactive threshold for patients is a key 
outcome of this treatment. Without OIT, patient ability to 
avoid hidden peanuts is based on previous experience 
and inconsistent labelling and advice from food 
providers.3,24–26 Consequently, accidental reactions often 
happen (14–55% per year8–10) and involve the use of 
health-care resources. Fear of death and severe reactions 
drives down quality of life.5,6
Peanut OIT raises the reactive threshold at least 
25-times so that 84–91% of participants can tolerate daily 
ingestion of 800 mg protein. Furthermore, 54–62% of 
children can tolerate a challenge with 1400 mg protein, 
roughly equivalent to ten peanuts. We showed previously 
that two-thirds of individuals who can tolerate 1400 mg 
could also tolerate 6000 mg protein (equivalent to 
38 peanuts). Those who could not had only mild 
reactions.18 These calculations are based on an average 
peanut containing 160 mg protein, although variation 
occurs up to 260 mg. This treatment therefore allows 
participants to eat large quantities of peanuts, above the 
levels present in contaminated snacks and meals, 
allowing them to eat more freely and enjoy a reduction 
in social restrictions. Consequently, our study conﬁ rms 
an improvement in food-allergy speciﬁ c quality of life, 
suggested by an earlier uncontrolled study of peanut 
OIT.27 Quality of life was measured on a validated 
disease-speciﬁ c six-point scale21 and the improvements 
evident in the active and control groups after intervention 
(–1·61, –1·41) are clinically meaningful, although 
participants were not masked to treatment allocation 
and this might have introduced bias. 
Our ﬁ ndings should be interpreted in the context of the 
study limitations. We did not mask treatment allocation. 
Instead we used a masked objective test to measure the 
primary outcome (ie, no reaction to peanut during 
DBPCFC). There was a small risk of bias as participants 
who knew they were receiving active treatment might 
have under-reported minor symptoms at the higher 
challenge doses, although these symptoms would have 
been uncommon and subjective. Additionally, during 
ﬁ rst phase, ten participants did not undergo a post-OIT 
challenge because they had withdrawn or not reached the 
target maintenance OIT dose at 6 months. It is probable 
that in the ﬁ rst phase the true response rate is lower than 
estimated; however, in the second phase, where there 
were few dropouts, we still noted a large eﬀ ect. A very 
conservative sensitivity analysis was done in which all 
the unobserved participants in the active group were 
imputed as not desensitised and all the unobserved 
participants in the control group were imputed as 
desensitised. The analysis gave a risk diﬀ erence of 0·41 
(95% CI 0·21–0·58), which supports the conclusions of 
our main analysis.
Since, to our knowledge, this is the ﬁ rst study of its 
type, our ﬁ ndings are relevant to the population studied, 
but will need conﬁ rmation in other subgroups of 
patients. Because of the signiﬁ cant risks involved, OIT 
should be restricted to specialist centres.
We studied desensitisation over a 6 month period, 
rather than tolerance after cessation of treatment, 
because stopping OIT after a median of 9 months has 
been shown to lead to loss of desensitisation.28 It is 
probable that long-term peanut protein ingestion will 
be needed to provide continued protection from 
accidental exposure, perhaps for several years. This 
view is supported by immunological investigation; 
during peanut OIT, we showed evidence of basophil 
and mast-cell desensitisation and other groups have 
shown a gradual change in peanut-speciﬁ c T-cell-
Panel: Research in context
Systematic review
We searched PubMed and the Cochrane database for English 
language publications with the MeSH terms “peanut oral 
immunotherapy”, “peanut desensitization”, and “peanut 
tolerance”. Date limits for our search were from January, 
1980, to August, 2013. A recent systematic review of studies 
of peanut oral immunotherapy (OIT) identiﬁ ed a single small 
randomised controlled study in 28 children.23 It suggested a 
positive eﬀ ect of peanut OIT but was not powered to 
estimate eﬃ  cacy. Interpretation of published studies has also 
been hampered by small size, exclusion of severely allergic 
children, and failure to conﬁ rm allergic status on enrolment 
by food challenge.
Interpretation
To our knowledge, we did the ﬁ rst phase 2 study appropriately 
powered to derive an accurate estimate of the eﬀ ect size of the 
treatment in children aged 7–15 years. By contrast with other 
studies, we assessed a representative UK population including 
children with severe reactions, with allergy conﬁ rmed by 
DBPCFC. 84% and 91% of participants could tolerate the 
equivalent of ﬁ ve peanuts per day, and a high rate of 
desensitisation (ability to tolerate the equivalent of roughly 
ten peanuts) was shown. There was a substantial eﬀ ect size, 
and improvement in quality of life with a good safety proﬁ le. 
Tolerance after cessation of OIT was not assessed. Our data 
apply to the population studied and the doses employed, and 
there is a need for replication and expansion of populations 
studied. This study shows that peanut immunotherapy is an 
eﬀ ective and well tolerated treatment in this age group. 
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surface markers from Th2 to Th1 phenotype.29 Long-
lived terminally diﬀ erentiated IgE secreting plasma 
cells survive in the bone marrow in this environment 
for years, consequently, peanut speciﬁ c IgE levels 
persist for several years after starting OIT, despite 
apparent clinical desensitisation.29
Unsurprisingly there were many more allergic events 
during active treatment than during periods of peanut 
avoidance. The safety data in this trial show most adverse 
events were mild and due to gastrointestinal symptoms 
(eg, oral itching), as expected from the route of 
administration. Skin reactions were uncommon 
(urticaria after 0·16% of doses). Reactions involving 
wheezing occurred after 0·41% of doses, or roughly one 
ﬁ fth of participants. Although wheezing could be taken 
as a sign of a more severe reaction, in all but one 
participant it was mild and responded to standard doses 
of inhaled bronchodilator drugs. One participant self-
administered adrenaline at home with good eﬀ ect on two 
occasions for wheezing after his peanut OIT doses—he 
was withdrawn from the study. No participants had 
hypotension. 
We previously devised a new regimen18 with a standard 
starting dose for all participants, because our pilot study17 
showed that tailoring the starting dose to individual 
thresholds commonly resulted in adverse events, even at 
low doses. This regime is therefore better tolerated and 
an improvement. From the limited data available in 
published work it is apparent that the speed of the 
updosing schedule has a greater negative eﬀ ect on safety 
and eﬃ  cacy than the size of the maintenance dose, with 
semi-rush regimens showing less eﬃ  cacy and more 
common reactions.28,29 We therefore used a gradual 
updosing regimen. 
Prognostic factors were explored with Tobit regression.22 
Treatment with OIT was, unsurprisingly, the most 
inﬂ uential positive factor. Serum peanut-speciﬁ c IgE, 
age, and family history were also associated with a 
negative eﬀ ect on NOAEL (weight had a weak eﬀ ect). 
These are all prognostic factors that one would intuitively 
think would make immunotherapy more diﬃ  cult, and 
need further study.
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